Skip to main content
Fig. 4 | Cell Communication and Signaling

Fig. 4

From: Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability

Fig. 4

D347-2761 overcame BTZ drug resistance in MM cells. A RPMI-8226 cell was dealt with 5 μM D347-2761 following 10 nM BTZ treatment and cell viability was measured by CCK8 assay. B Flow cytometry assay analysis of apoptotic cell rate in RPMI-8226 cells following 5 μM D347-2761 and/or 10 nM BTZ treatment. C RPMI-8226/BTZ100 cell was treated by different dose of D347-2761 (5 μM, 10 μM, 20 μM and 30 μM) and cell viability was measured by CCK8 assay. D-E. Flow cytometry assay analysis of apoptotic cell rate in RPMI-8226/BTZ100 cells following different concentration of D347-2761 (5 μM, 10 μM and 15 μM) for 48 h, or treated by 5 μM D347-2761 and/or 10 nM BTZ treatment. F Western blot analysis of γH2AX expression in RPMI-8226/BTZ100 cells following different dose of D347-2761 or BTZ and combination (10 μM D347-2761 and 10 nM BTZ). β-actin was used to be internal control. Error bars: mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X